Literature DB >> 8577883

Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing.

R I Dafters1.   

Abstract

In two experiments it was found that the hyperthermia which follows MDMA ("Ecstasy") results from an interaction of direct pharmacological effect of the drug and the prevailing environmental conditions in which it is administered. In Experiment 1, rats given fixed doses of either 2.5, 5.0 or 7.5 mg/kg MDMA or saline were injected on different days at ambient temperatures (Ta's) of 11, 24, and 30 degrees C. At each Ta drinking water was freely available following dosing on one session and temporarily unavailable on a second. The hyperthermic and hyperkinetic responses were monitored using remote biotelemetry. Experiment 2 used a between-subject design in which each group of rats received a standard 7.5 mg/kg dose of MDMA administered at only one of the three levels of Ta(24 degrees C) and at only one level of the water-availability factor. Dosing in some groups was continued for a further 13 days to test for tolerance or sensitization effects. Ambient temperature significantly affected the magnitude of the hyperthermia but not the hyperkinesis. Water deprivation during the drugged period significantly augmented the hyperthermia, but only in the high Ta (30 degrees C.) condition. Chronic dosing produced sensitization of both hyperthermic and hyperkinetic responses. The findings indicate that ambient temperature, water consumption and frequency of drug use affect the hyperthermia which follows MDMA administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8577883     DOI: 10.1016/0031-9384(95)00136-7

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  42 in total

1.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  Cm Hysek; Y Schmid; A Rickli; L D Simmler; M Donzelli; E Grouzmann; M E Liechti
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.

Authors:  Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

3.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation.

Authors:  Cédric M Hysek; Yasmin Schmid; Anna Rickli; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Initial deficit and recovery of function after MDMA preexposure in rats.

Authors:  K A Brennan; S Schenk
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

Review 5.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

6.  Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Hyponatraemia must be treated with low water input.

Authors:  B Wilkins
Journal:  BMJ       Date:  1996-09-14

Review 7.  Neurotoxicology of Synthetic Cathinone Analogs.

Authors:  Mariana Angoa-Pérez; John H Anneken; Donald M Kuhn
Journal:  Curr Top Behav Neurosci       Date:  2017

8.  Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits.

Authors:  N P Pedersen; W W Blessing
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 9.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

10.  Studies on the role of dopamine D1 receptors in the development and expression of MDMA-induced behavioral sensitization in rats.

Authors:  María Ramos; Beatriz Goñi-Allo; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.